Indivior has discontinued sales and marketing for its schizophrenia drug Perseris. This last decision, prompted by increased payor management impacts, is expected to make the product financially unviable… read more.
Laboratorios Farmacéuticos Rovi, S.A. has announced that the FDA has authorised the marketing of Risvan (risperidone ISM ) for the treatment of schizophrenia in adults. Risperidone ISM is… read more.
Young men with cannabis (marijuana) use disorder have an increased risk of developing schizophrenia, according to a study led by researchers at the Mental Health Services in the… read more.
People with severe mental illness are less likely to attend cancer screening compared to those who do not have such conditions, according to new research from the University… read more.
AbbVie announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (Vraylar) to the FDA for the adjunctive treatment of major depressive disorder (MDD) in… read more.
Ketamine is effective for the acute treatment of severe suicidal ideation, researchers reported on February 2, 2022 in The BMJ/British Medical Journal. “This study confirmed in a large… read more.
New research published in the Proceedings of the National Academy of Sciences shows that examining genetic mutations in individuals with severe schizophrenia can improve the ability to detect disease-associated rare… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the FDA has approved long-acting atypical antipsychotic Invega Hafyera (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the… read more.
Alkermes announced that the FDA has approved Lybalvi (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder,… read more.
Article written by Gary Finnegan. It is well-established that the children of people with serious mental health issues can be affected by their parents’ illness. Now new research… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
